Monday, April 20, 2026 – PLAINSBORO, NJ and BAGSVÆRD, Denmark, April 2, 2026 /PRNewswire/ -- Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association’s annual conference in San Diego showing that Wegovy® (semaglutide) tablets 25...
Monday, April 20, 2026 – (MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...
Monday, April 20, 2026 – Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella review draws attention to safety concerns regarding the use of this GLP medication, alongside a mix of potential benefits.
Monday, April 20, 2026 – (MedPage Today) -- Novo Nordisk said its semaglutide (Wegovy) pill outperformed recently approved orforglipron (Foundayo) in weight loss and tolerability in an indirect comparison using clinical trial data, and the company launched multi-month...
Monday, April 20, 2026 – (MedPage Today) -- Integrating the most effective obesity treatments into cancer survivorship offers "an unprecedented opportunity" to improve long-term outcomes in cancer, including survival, a trio of obesity and oncology specialists argued in...
Monday, April 20, 2026 – Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.
Monday, April 20, 2026 – By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.
Monday, April 20, 2026 – Here’s everything we know so far.
Monday, April 20, 2026 – (MedPage Today) -- GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 diabetes, a target trial emulation suggested.
Using U.S. electronic health record data, the incidence of...
Monday, April 20, 2026 – A newly discovered molecule could reshape the future of weight loss treatments by mimicking the powerful appetite-suppressing effects of drugs like Ozempic — but without many of the unpleasant side effects. Identified using artificial intelligence, this tiny peptide, called BRP, appears to act directly on the brain’s appetite-control center, helping animals eat less and lose fat without nausea or muscle loss.